CoChat

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

Open access
Whittam, Daniel H, Cobo-Calvo, Alvaro, Lopez-Chiriboga, A Sebastian, Pardo, Santiago, Gornall, Matthew, Cicconi, Silvia, Brandt, Alexander, Berek, Klaus, Berger, Thomas, Jelcic, Ilijas, Gombolay, Grace, Oliveira, Luana Micheli, Callegaro, Dagoberto, Kaneko, Kimihiko, Misu, Tatsuro, Capobianco, Marco, Gibbons, Emily, Karthikeayan, Venkatraman, Brochet, Bruno, Audoin, Bertrand, Mathey, Guillaume, Laplaud, David, Thouvenot, Eric, Cohen, Mikaël, Tourbah, Ayman, Maillart, Elisabeth, Ciron, Jonathan, Deschamps, Romain, Biotti, Damien, Rostasy, Kevin, Neuteboom, Rinze, Hemingway, Cheryl, Forsyth, Rob, Matiello, Marcelo, Webb, Stewart, Hunt, David, Murray, Katy, Hacohen, Yael, Lim, Ming, Leite, M Isabel, Palace, Jacqueline, Solomon, Tom, Lutterotti, Andreas, Fujihara, Kazuo, Nakashima, Ichiro, Bennett, Jeffrey L, Pandit, Lekha, Chitnis, Tanuja, Weinshenker, Brian G, Wildemann, Brigitte, Sato, Douglas Kazutoshi, Kim, Su-Hyun, Huda, Saif, Kim, Ho Jin, Reindl, Markus, Levy, Michael, Jarius, Sven, Tenembaum, Silvia, Paul, Friedemann, Pittock, Sean, Marignier, Romain, Jacob, Anu · 2020 · Multiple Sclerosis and Related Disorders
Cited by 184

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Objective: To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). Methods: Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model). Results: Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3–14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3–24.9) months. In this ‘relapsing group’, relapse rate declined by 37% (95%CI=19–52%, p<0.001) overall, 63% (95%CI=35–79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2–44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses. Conclusion: RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.msard.2020.102251

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 184

Metadata

Authors
Whittam, D. H., Cobo-Calvo, A., Lopez-Chiriboga, A. S., Pardo, S., Gornall, M., Cicconi, S., Brandt, A., Berek, K., Berger, T., Jelcic, I., Gombolay, G., Oliveira, L. M., Callegaro, D., Kaneko, K., Misu, T., Capobianco, M., Gibbons, E., Karthikeayan, V., Brochet, B., Audoin, B., Mathey, G., Laplaud, D., Thouvenot, E., Cohen, M., Tourbah, A., Maillart, E., Ciron, J., Deschamps, R., Biotti, D., Rostasy, K., Neuteboom, R., Hemingway, C., Forsyth, R., Matiello, M., Webb, S., Hunt, D., Murray, K., Hacohen, Y., Lim, M., Leite, M. I., Palace, J., Solomon, T., Lutterotti, A., Fujihara, K., Nakashima, I., Bennett, J. L., Pandit, L., Chitnis, T., Weinshenker, B. G., Wildemann, B., Sato, D. K., Kim, S.-H., Huda, S., Kim, H. J., Reindl, M., Levy, M., Jarius, S., Tenembaum, S., Paul, F., Pittock, S., Marignier, R., & Jacob, A.
Venue
Multiple Sclerosis and Related Disorders
Publisher
Elsevier BV
Published
2020-09
Volume
44
Pages
102251
ISSN
2211-0348 (ISSN-L)
OpenAlex
W3034095681
Cited by
184
References
7
FWCI
15.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. https://app.cochat.ai/papers/10.1016/j.msard.2020.102251
The paper
Whittam, D. H., Cobo-Calvo, A., Lopez-Chiriboga, A. S., Pardo, S., Gornall, M., Cicconi, S., Brandt, A., Berek, K., Berger, T., Jelcic, I., Gombolay, G., Oliveira, L. M., Callegaro, D., Kaneko, K., Misu, T., Capobianco, M., Gibbons, E., Karthikeayan, V., Brochet, B., . . . Jacob, A. (2020). Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders. https://doi.org/10.1016/j.msard.2020.102251

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.